Nordion, AECL settle reactor lawsuits
Article Thumbnail ImageAugust 20, 2013 -- Nordion and Atomic Energy of Canada (AECL) have entered into an agreement to resolve a dispute over nuclear facilities used to produce radioisotopes.

To get access to this article and all of the content on, create a free account or sign-in now.

Member Sign In:
  MemberID or E-mail Address:

New Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • Under the terms of the settlement, Nordion will receive $15 million Canadian ($14.4 million U.S.) in cash from AECL, while AECL will release its claim against Nordion of approximately $47 million ($46.1 million U.S.) for arbitration costs.

    In addition, Nordion has withdrawn its lawsuit against AECL related to the Multipurpose Applied Physics Lattice Experiment (MAPLE) reactor, which AECL had planned to build to replace an aging reactor that is one of the primarily sources in North America for molybdenum-99 (Mo-99). Mo-99 is used to produce technetium-99m, which is commonly used in cardiac nuclear medicine procedures. AECL's cancellation of the project triggered the dispute between the firms.

    The release includes Nordion's claim for damages against AECL of approximately $244 million ($234.2 million U.S.) and AECL's counterclaim for damages against Nordion of $80 million ($76.8 million U.S.).

    The amended and restated isotope supply agreement is a nonexclusive agreement for medical isotope supply by AECL to Nordion that ends on October 31, 2016. The pact may be terminated if, among other possibilities, Nordion establishes an alternative supply of isotopes, AECL's isotope production facilities are permanently shut down, or Nordion fails to meet a minimum purchase quantity.

    In a prepared statement, Nordion CEO Steve West said the "resolution provides greater clarity for Nordion and removes the uncertainty and liability around these matters. Nordion is now better positioned to focus on the needs and priorities of our business, including our important relationship with AECL, with a continued view to enhancing shareholder value and creating new opportunities for the company and our customers."

    || About || Advertising || || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 All Rights Reserved.